82
Panelists highlight how real-world outcomes shape patient discussions, especially when setting realistic expectations about efficacy, safety, and quality of life with third-line options.
They note that real-world evidence with trifluridine/tipiracil plus bevacizumab and with fruquintinib confirms trial findings, providing confidence to patients about likely benefits.
By framing treatment conversations around both clinical data and real-world outcomes, clinicians can foster shared decision-making that aligns patient goals with available therapies.
